Market Overview

Global Orphan Drugs Market Analysis & Outlook 2018-2022 - Key Players are Roche Holding, Novartis International, Bristol-Myers Squibb and Celgene Corp -


The "Global
Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)"

report has been added to's

Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)
provides an extensive research and detailed analysis of the present
market along with future outlook. The report discusses the major growth
drivers and challenges of the market, covering the US, Europe and Asia
along with the global market.

Orphan drug market is likely to witness a growth in future with
increasing development and approvals of ultra-rare drugs and rising
developments in drugs for rare blood disease. The US and Europe are the
major contributors to the global orphan drugs market supported by
increased numbers of orphan drug designations. Asia is likely to
experience further growth with increasing orphan designations in Japan
and improving healthcare facilities.

The global orphan drugs market is expected to grow in future due to
prolonged orphan drug market exclusivity, increasing sales of
prescription drugs, attractive orphan drug policies, rising healthcare
expenditure, improving economies and increasing prevalence of chronic

Key trends & development of this market include rise in orphan drug
approvals, accelerating pipeline sales of orphan drugs, development of
drug therapies and rising scope in gene therapy. However, there are some
factors which can hinder growth of the market including high costs of
drugs, increased competition from generic industry, insufficient disease
information & research participants and deficiency of diagnostic systems
and trained professionals.

The report profiles key players of the market including Roche holding
AF, Novartis International AG, Bristol-Myers Squibb and Celgene

Key Topics Covered:

1. Overview

2. Global Orphan Drugs Market

3. Regional Market Analysis

4. Market Dynamics

5. Competitive Landscape

6. Company Profiles

  • Novartis International AG
  • Roche Holding AG
  • Bristol-Myers Squibb
  • Celgene Corporation

For more information about this report visit

View Comments and Join the Discussion!